Tomas Turner

Dr. Tomas Turner

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2023 in Injury
Verified
Journal Article
Closed access
AZAlvaro Zamorano
Alvaro Zamorano
CACarlos Felipe Albarrán
Carlos Felipe Albarrán
MVMatías A. Vaccia
Matías A. Vaccia
RPRodrigo Ignacio Parra
Rodrigo Ignacio Parra
TTTomas Turner
Tomas Turner
LBLuis A. Bahamonde
Luis A. Bahamonde

1 October 2025 in OTA International
Verified
Journal Article
Open access
AZAlvaro Zamorano
Alvaro Zamorano
MVMatías A. Vaccia
Matías A. Vaccia
RPRodrigo Ignacio Parra
Rodrigo Ignacio Parra
TTTomas Turner
Tomas Turner
IRIgnacio Rivera
Ignacio Rivera
LBLuis Bahamonde
Luis Bahamonde
Introduction: Gustilo–Anderson type IIIB open tibial fractures carry a high risk of fracture-related infection (FRI) due to extensive soft tissue damage and frequent delays in coverage. Although early orthoplastic intervention lowers infection rates, many trauma centers lack the resources for same-day or early flap coverage. This study aimed to assess the relationship between timing of flap coverage and FRI risk in a young, healthy population, and to define a clinically relevant therapeutic window. Materials and Methods: A retrospective cohort study was conducted at a single Level I trauma center (2012–2023). Patients with GA IIIB tibial fractures were treated under a standardized protocol with strict inclusion criteria. Timing of flap coverage was analyzed using Levene test, Student t test, and ROC curve analysis with the Youden index to determine the optimal infection-risk threshold. Results: Out of 332 open tibial fractures, 41 patients with GA IIIB injuries met inclusion criteria. Mean time to coverage was 24.6 days. FRI occurred in 15 patients (36.6%). Delayed coverage was significantly associated with FRI ( P < 0.001). ROC analysis showed an AUC of 0.83; the Youden index identified <12 days as the optimal cutoff (100% sensitivity, 34.6% specificity). None of the 10 patients treated within 12 days developed FRI, versus 56.6% in those treated later ( P < 0.05). Conclusions: Coverage within 12 days minimizes infection risk in GA IIIB tibial fractures. Although immediate coverage remains ideal, a defined 12-day window offers practical guidance, especially where early orthoplastic care is not feasible.

22 May 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
AZAlvaro Zamorano
Alvaro Zamorano
MVMatías A. Vaccia
Matías A. Vaccia
CACarlos Felipe Albarrán
Carlos Felipe Albarrán
RPRodrigo Ignacio Parra
Rodrigo Ignacio Parra
TTTomas Turner
Tomas Turner
LBLuis Bahamonde
Luis Bahamonde
Introduction: Open tibial fractures carry a high risk of fracture-related infection (FRI), and prevention typically relies on early antibiotics and debridement. However, achieving optimum local antibiotic concentration remains challenging. Gentamicin-coated intramedullary nails (GCN) have been developed to prevent biofilm formation, showing short-term efficacy without interfering with fracture healing. Medium- and long-term data on GCN use are limited. This study aimed to assess the effectiveness and safety of GCN in medium-term follow-up. Methods: A prospective cohort study of patients with open tibial fractures was treated with GCN under a standardized protocol, with a minimum follow-up of 24 months. Patients with traumatic amputations, protocol infringement, or loss of follow-up were excluded. The analysis assessed overall FRI incidence by Gustilo–Anderson (GA) classification. Results: Of 907 patients, 139 were included, with 2 lost to follow-up. The overall FRI incidence was 8.8%, the average healing time was 34.3 weeks, and the non-union rate was 2.2%. FRI incidence by GA classification was 0% in GA I, 2.9% in GA II, 2.9% in GA IIIA, 44.4% in GA IIIB, and 33.3% in GA IIIC. External fixation (EF) was required in 45.2% of cases, with 16.1% developing FRI (14.3% in GA II, 2.8% in GA IIIA, 50% in GA IIIB, and 33.3% in GA IIIC). In non-EF cases, FRI occurred in 2.7% of patients (2.9% in GA IIIA and 25% in GA IIIB). No adverse effects were reported due to locally administered gentamicin. Conclusions: In the medium term, GCN has consistently demonstrated safety and efficacy in preventing FRI in open tibial fractures, particularly in GA IIIA cases, even with the use of temporary EF. These findings highlight its potential as a valuable tool in managing open tibial fractures. However, further studies with long-term outcomes are needed to evaluate its effectiveness in GA IIIB and IIIC fractures.